Please assess the completion status of the following clinical trial:

Trial Title: Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Core Inclusion Criteria:~* Histologically confirmed PD-L1 status defined NSCLC. Biopsy must be within 70 days of first treatment with pembrolizumab.~* ECOG performance status 2.~* Life expectancy \> 12 weeks.~* Uni-dimensionally measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1~* Computerised Tomography (CT) scan of chest and abdomen within 28 days of starting pembrolizumab.~* Adequate haematological function:~  * Platelet count ≥100 x 109 /L.~ * Neutrophils ≥1.5 x 109/L.~ * Haemoglobin ≥ 90 g/L.~* Adequate hepatic function:~  * Serum bilirubin ≤1.5 x upper limit of normal (ULN).~ * Serum transaminases ≤2.5 x ULN.~* Adequate renal function: Creatinine clearance \<1.5 times ULN concurrent with creatinine clearance \>50 ml/min.~* Provision of signed and dated, written informed consent prior to any trial specific procedures, sampling and analyses.~Core Exclusion Criteria:~* Patients who do not meet the criteria of performance status = 2 on the ECOG Performance scale.~* Untreated symptomatic brain or leptomeningeal metastatic disease.~* Medical or psychiatric conditions compromising informed consent.~* Any medical condition which in the opinion of the investigator would compromise the ability of the patient to participate in the trial or which would jeopardise compliance with the protocol.~* Radiotherapy within 28 days of trial treatment.~* Active autoimmune disease that has required systemic treatment in past 2 years~* Chronic usage of steroids or other immunosuppressant medication.~* Previous history of pneumonitis.~* Any evidence of clinical autoimmunity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pembrolizumab (Type: EXPERIMENTAL): Pembrolizumab: 200 mg Q3W, intravenous administration for a maximum of 2 years, or until progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).